PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33829270-0	2021	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.	osimertinib	8-19	insulin like growth factor 1 receptor	Homo sapiens	103-108	
33829270-13	2021	She was re-administered osimertinib since EGFR-TKIs and IGF1R inhibitor combination therapy was impossible in clinical practice.	osimertinib	24-35	insulin like growth factor 1 receptor	Homo sapiens	56-61	
31758670-0	2020	Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.	osimertinib	83-94	insulin like growth factor 1 receptor	Homo sapiens	14-51	
32929081-4	2020	IGF-1R maintains association with EGFR and adaptor proteins, including Gab1 and IRS1, in the presence of osimertinib and restores the survival signal.	osimertinib	105-116	insulin like growth factor 1 receptor	Homo sapiens	0-6	
32929081-5	2020	In AXL-low-expressing EGFRmut-LC cell-derived xenograft and patient-derived xenograft models, transient IGF-1R inhibition combined with continuous osimertinib treatment could eradicate tumors and prevent regrowth even after the cessation of osimertinib.	osimertinib	241-252	insulin like growth factor 1 receptor	Homo sapiens	104-110	
31941753-0	2020	IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer.	osimertinib	79-90	insulin like growth factor 1 receptor	Homo sapiens	24-29	
31941753-9	2020	Both of our established lung cancer cells and patient-derived lung cancer cells demonstrated IGF2 autocrine-mediated IGF1R pathway activation as a mechanism of osimertinib resistance.	osimertinib	160-171	insulin like growth factor 1 receptor	Homo sapiens	117-122	
31941753-13	2020	Here, we report for the first time the IGF2 autocrine-mediated IGF1R activation as a nongenetic mechanism of osimertinib resistance in lung cancer at a clinically relevant level.	osimertinib	109-120	insulin like growth factor 1 receptor	Homo sapiens	63-68	
31941753-14	2020	IMPLICATIONS: Using comprehensive protein phosphorylation array and patient-derived lung cancer cells, we found that IGF2 autocrine-mediated IGF1R pathway activation is a clinically relevant and common mechanism of acquired resistance to osimertinib.	osimertinib	238-249	insulin like growth factor 1 receptor	Homo sapiens	141-146	
31758670-7	2020	Knockdown of IGF1R by siRNA as well as inhibition of IGF1R activation by linstinib (IGF1R inhibitor) significantly restored the sensitivity to osimertinib.	osimertinib	143-154	insulin like growth factor 1 receptor	Homo sapiens	13-18	
31758670-7	2020	Knockdown of IGF1R by siRNA as well as inhibition of IGF1R activation by linstinib (IGF1R inhibitor) significantly restored the sensitivity to osimertinib.	osimertinib	143-154	insulin like growth factor 1 receptor	Homo sapiens	53-58	
31758670-7	2020	Knockdown of IGF1R by siRNA as well as inhibition of IGF1R activation by linstinib (IGF1R inhibitor) significantly restored the sensitivity to osimertinib.	osimertinib	143-154	insulin like growth factor 1 receptor	Homo sapiens	53-58	
31758670-8	2020	Immunohistochemical analysis revealed that the expression level of phosphorylated IGF1R was higher in the tumor specimen from the EGFR-mutant NSCLC patient with acquired resistance to osimertinib than in the specimen collected prior to the treatment.	osimertinib	184-195	insulin like growth factor 1 receptor	Homo sapiens	82-87	
31758670-9	2020	CONCLUSIONS: IGF1R activation could occur following treatment with osimertinib in EGFR-mutant NSCLC with T790M mutation, and might be one of the mechanisms underlying osimertinib resistance.	osimertinib	67-78	insulin like growth factor 1 receptor	Homo sapiens	13-18	
31758670-9	2020	CONCLUSIONS: IGF1R activation could occur following treatment with osimertinib in EGFR-mutant NSCLC with T790M mutation, and might be one of the mechanisms underlying osimertinib resistance.	osimertinib	167-178	insulin like growth factor 1 receptor	Homo sapiens	13-18	
31758670-10	2020	Combined treatment of osimertinib and IGF1R inhibitor might be effective in overcoming the acquired resistance to osimertinib induced by IGF1R activation.	osimertinib	22-33	insulin like growth factor 1 receptor	Homo sapiens	137-142	
31758670-10	2020	Combined treatment of osimertinib and IGF1R inhibitor might be effective in overcoming the acquired resistance to osimertinib induced by IGF1R activation.	osimertinib	114-125	insulin like growth factor 1 receptor	Homo sapiens	38-43	
31758670-10	2020	Combined treatment of osimertinib and IGF1R inhibitor might be effective in overcoming the acquired resistance to osimertinib induced by IGF1R activation.	osimertinib	114-125	insulin like growth factor 1 receptor	Homo sapiens	137-142	
34498213-12	2021	After exposure to the osimertinib/bevacizumab combination, the main secondary alterations were MET amplification, STAT3, IGF1R, PTEN, and PDGFR.	osimertinib	22-33	insulin like growth factor 1 receptor	Homo sapiens	121-126